Physician profile
Michael Macklin
NPI 1194287185
$47,933.59
in general payments reported to CMS, 2019-2025
19 companies · $42K in 2025
The $42K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $124 · 2023: $1,595 · 2024: $4,330 · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Consulting Fee: $7,237 · Food and Beverage: $6,375 · Travel and Lodging: $5,067 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,032.00 |
| Consulting Fee | $7,236.67 |
| Food and Beverage | $6,374.84 |
| Travel and Lodging | $5,067.43 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $43,199.19 | 2023-2025 | Uplizna, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $936.48 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $756.67 | 2024-2025 | |
| Abbvie INC. | $599.45 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $587.07 | 2023-2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $401.36 | 2024-2025 | Ultomiris, Soliris |
| Medtronic, INC. | $305.00 | 2025 | |
| Glaxosmithkline, LLC. | $263.22 | 2022-2025 | Benlysta, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $191.68 | 2022-2023 | Cuvitru, Glassia |
| E.R. Squibb & Sons, L.L.C. | $170.26 | 2024-2025 | Orencia |
| Actelion Pharmaceuticals US, INC. | $162.73 | 2023 | Uptravi, Opsumit |
| Genzyme Corporation | $99.28 | 2023-2024 | |
| Inogen, INC. | $77.90 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Genentech, INC. | $61.27 | 2025 | Gazyva |
| Argenx US, INC. | $29.62 | 2025 | Vyvgart Hytrulo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $25.57 | 2025 | Brinsupri |
| Janssen Biotech, INC. | $25.36 | 2023 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $20.90 | 2022 | |
| Genentech USA, INC. | $20.58 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Macklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.